natgillin/translations-raw huggingface dataset:
In a 6-month (3 treatment cycles) study of TOBI Podhaler versus tobramycin nebuliser solution, which included a majority of tobramycin-experienced adult patients with chronic pulmonary P. aeruginosa infection, the suppression of sputum P. aeruginosa density was similar across age groups in both arms; however the increase from baseline FEV1 was larger in younger age groups (6 - <20) than in the adult subgroup (20 years and older) in both arms. 
U 6-mjesečnom (3 ciklusa liječenja) ispitivanju TOBI Podhalera u usporedbi s tobramicin otopinom za nebulizator, koje je uključivalo većinu odraslih bolesnika koji su imali iskustva s tobramicinom i kroničnu plućnu infekciju bakterijom P. aeruginosa, supresija gustoće P. aeruginosa u sputumu bila je slična u različitim dobnim grupama u obje skupine; međutim, povećanje u odnosu na početnu vrijednost FEV1 bilo je veće u mlađim dobnim grupama (6 - <20) nego u odrasloj grupi (20 godina i stariji) u obje terapijske skupine.
TOBI Podhaler is a powder for inhalation that is filled into capsules. 
TOBI Podhaler je prašak za inhalaciju koji se nalazi u kapsulama.
In case of signs of acute toxicity, immediate withdrawal of TOBI Podhaler and testing of renal function are recommended. 
U slučaju znakova akutne toksičnosti, preporučuje se hitno prekidanje primjene TOBI Podhalera i ispitivanje bubrežne funkcije.
The extent of systemic exposure (AUC) was also similar for the 112 mg TOBI Podhaler dose and the 300 mg tobramycin nebuliser solution dose. 
Razmjer sistemske izloženosti (AUC) bio je također sličan za dozu od 112 mg TOBI Podhalera i za dozu od 300 mg tobramicin otopine za nebulizator.
If the capsule is punctured but still contains some powder, place it back into the inhaler and take another two inhalations from the capsule. 
Ako je kapsula probušena, ali još uvijek sadrži nešto praška, vratite je u inhalator i napravite još dvije inhalacije iz kapsule.
Haemoptysis is a complication in cystic fibrosis and is more frequent in adults. 
Hemoptiza je komplikacija kod cistične fibroze i učestalija je u odraslih osoba.
Treatment with TOBI Podhaler for 28 days resulted in a statistically significant reduction in P. aeruginosa sputum density (mean difference with placebo about 2.70 log10 in colony forming units/CFUs). 
Liječenje TOBI Podhalerom tijekom 28 dana rezultiralo je statistički značajnim smanjenjem gustoće P. aeruginosa u sputumu (srednja razlika s placebom oko 2,70 log10 jedinica koje tvore kolonije/CFU (eng. colony forming unit)).
If you experience any of these, stop taking TOBI Podhaler and tell your doctor straight away. 
Ako osjetite bilo što od toga, prestanite uzimati TOBI Podhaler i odmah se obratite svom liječniku.
Fully exhale away from the inhaler. 
Potpuno izdahnite dalje od inhalatora.
In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids and macrolides, no evidence of drug interactions with these medicines was identified. 
Podhaler i nastavili uzimati alfa dornazu, bronhodilatatore, inhalacijske kortikosteroide i makrolide nisu pronađeni dokazi interakcija s tim lijekovima.
Ototoxicity, manifested as both auditory toxicity (hearing loss) and vestibular toxicity, has been reported with parenteral aminoglycosides. 
Ototoksičnost, koja se manifestira kao auditivna toksičnost (gubitak sluha) i kao vestibularna toskičnost, zabilježena je vezano uz primjenu parenteralnih aminoglikozida.
• Always keep the capsules in the capsule card until when you need to use them. 
• Uvijek držite kapsule u kartici s kapsulama do trenutka kada ih trebate upotrijebiti.
Adverse drug reactions in Table 1 are listed according to system organ classes in MedDRA. 
Nuspojave u Tablici 1 navedene su prema klasifikaciji organskih sustava MedDRA-e.
Treatment with TOBI Podhaler should be continued on a cyclical basis for as long as the physician considers the patient is gaining clinical benefit from the treatment with TOBI Podhaler. 
Liječenje TOBI Podhalerom treba nastaviti ciklički dokle god liječnik smatra da bolesnik ima kliničke koristi od liječenja TOBI Podhalerom.
Your doctor will supervise your first dose of TOBI Podhaler and check your lung function before and after dosing. 
Liječnik će nadzirati Vašu prvu dozu TOBI Podhalera i provjeriti
As tobramycin is not metabolised, an effect of hepatic impairment on the exposure to tobramycin is not expected. 
Budući da se tobramicin ne metabolizira, ne očekuje se utjecaj oštećenja jetre na izloženost tobramicinu.
• hearing problems (including noises in the ears and dizziness) 
• poteškoće sa sluhom (uključujući zvukove u ušima i omaglicu) • poteškoće s bubrezima
If you are taking one or more of the above medicines, discuss with your doctor before you take TOBI Podhaler. 
Ako uzimate jedan ili više gore navedenih lijekova, razgovarajte sa svojim liječnikom prije nego uzmete TOBI Podhaler.
Serum concentrations 
Koncentracije u serumu
In children under 13 years of age, discontinuations were more frequent in the TOBI nebuliser solution arm whereas in patients aged 13 to 19, discontinuation rates with both formulations were similar. 
U djece mlađe od 13 godina prekidi su bili učestaliji u skupini koja je primala TOBI otopinu za nebulizator, dok su među bolesnicima u dobi od 13 do 19 godina stope prekida bile slične za obje formulacije.
1 reserve inhaler inside. 
Sadrži 1 rezervni inhalator.
Holding the body of the inhaler, unscrew and remove the mouthpiece from the inhaler body. 
Držeći tijelo inhalatora, odvijte i maknite nastavak za usta s tijela inhalatora.
In patients with any evidence of auditory dysfunction, or those with a predisposing risk, it may be necessary to consider audiological assessment before initiating TOBI Podhaler therapy. 
U bolesnika s bilo kojim dokazom auditivne disfunkcije, ili u onih s predisponirajućim rizikom, treba razmotriti audiološku obradu prije početka terapije TOBI Podhalerom.
TOBI Podhaler is used in patients aged 6 years and older who have cystic fibrosis to treat lung infections caused by bacteria called Pseudomonas aeruginosa. 
TOBI Podhaler se koristi u bolesnika u dobi od 6 i više godina koji imaju cističnu fibrozu, za liječenje plućnih infekcija uzrokovanih bakterijom koje se zove Pseudomonas aeruginosa.
In the absence of conventional susceptibility breakpoints for the inhaled route of administration, caution must be exercised in defining organisms as susceptible or insusceptible to inhaled tobramycin. 
U nedostatku konvencionalnih granica osjetljivosti kod inhalacijske primjene, moraju se primijeniti mjere opreza kod definiranja organizama kao osjetljivih ili neosjetljivih na inhalirani tobramicin.
No studies have been performed on patients with hepatic impairment. 
Nisu obavljena ispitivanja u bolesnika s oštećenjem jetre.
If an allergic response is suspected, TOBI Podhaler should be discontinued. 
Ako postoji sumnja na alergijsku reakciju, uzimanje TOBI Podhalera mora se prekinuti.
Bronchospasm should be treated as medically appropriate. 
Bronhospazam se mora liječiti na klinički primjeren način.
• Hold the inhaler with the mouthpiece pointing down 
• Držite inhalator s nastavkom za usta okrenutim prema dolje
Patients who use TOBI Podhaler during pregnancy, or become pregnant while taking TOBI Podhaler, should be informed of the potential hazard to the foetus. 
Podhaler tijekom trudnoće, ili koje zatrudne dok uzimaju TOBI Podhaler, moraju biti obaviještene o potencijalnoj opasnosti za plod.
Patients who were randomised to the placebo treatment group received placebo during the first treatment cycle and TOBI Podhaler in the subsequent two cycles. 
Bolesnici koji su bili randomizacijom dodijeljeni u placebo terapijsku skupinu primali su placebo tijekom prvog terapijskog ciklusa, te TOBI Podhaler u naredna dva ciklusa.
Over half of the patients in both the TOBI Podhaler and TOBI nebuliser solution treatment groups received new (additional) anti-pseudomonal antibiotics (64.9% and 54.5% respectively, the difference consisting mainly of oral ciprofloxacin use). 
Više od polovice bolesnika i u terapijskoj skupini koja je primala TOBI Podhaler i u skupini koja je primala TOBI otopinu za nebulizator primilo je nove (dodatne) antipseudomonalne antibiotike (64,9% odnosno 54,5%, razlika se sastojala uglavnom od peroralne primjene ciproflaksacina).
It is not known whether inhaling this medicine when you are pregnant causes side effects. 
Nije poznato uzrokuje li inhalacija ovog lijeka kada ste trudni nuspojave.
Inhaling medicines can also cause cough and this can happen with TOBI Podhaler. 
Inhalacija lijekova može uzrokovati i kašalj, a to se može dogoditi i s TOBI Podhalerom.
Contents of the pack and other information What TOBI Podhaler contains 
Sadržaj pakiranja i druge informacije Što TOBI
TOBI Podhaler capsules must always be stored in the blister (capsule card), and only removed immediately before use. 
TOBI Podhaler kapsule moraju se uvijek čuvati u blisteru (kartici s kapsulama) i izvaditi tek neposredno prije primjene.
What you need to know before you take TOBI Podhaler Do not take TOBI Podhaler 
Što morate znati prije nego počnete uzimati TOBI Podhaler Nemojte uzimati TOBI Podhaler
Inspect the used capsule. 
Provjerite upotrijebljenu kapsulu.
Safety and efficacy have not been studied in patients with forced expiratory volume in 1 second (FEV1) <25% or >75% predicted, or patients colonised with Burkholderia cepacia. 
1 sekundi (FEV1) <25% ili >75% predviđenog, ili u bolesnika koloniziranih bakterijom Burkholderia cepacia.
• unusual difficulty in breathing with wheezing or coughing, chest tightness 
• neuobičajene poteškoće pri disanju uz piskanje ili kašalj, stezanje u prsnom košu
Treatment with both TOBI Podhaler and tobramycin 300 mg/5 ml nebuliser solution (TOBI) resulted in relative increases from baseline to day 28 of the third treatment cycle in percent predicted FEV1 of 5.8% and 4.7%, respectively. 
Liječenje TOBI Podhalerom i tobramicin 300 mg/5 ml otopinom za nebulizator (TOBI) rezultiralo je relativnim povećanjem od početne vrijednosti do 28. dana trećeg ciklusa terapije u postotku predviđenog FEV1 od 5,8% odnosno 4,7%.
The TOBI Podhaler Phase III clinical development programme consisted of two studies and 612 treated patients with a clinical diagnosis of CF, confirmed by quantitative pilocarpine iontophoresis sweat chloride test or well-characterised disease causing mutations in each cystic fibrosis transmembrane regulator (CFTR) gene, or abnormal nasal transepithelial potential difference characteristic of CF. 
Podhalera sastojao se od dva ispitivanja i 612 liječenih bolesnika s kliničkom dijagnozom CF-a, potvrđenom kvantitativnom pilokarpinskom iontoforezom za određivanje klorida u znoju ili dobro karakteriziranim mutacijama koje uzrokuju bolest u svakom genu za cistično-fibrozni transmembranski regulator provodljivosti (CFTR), ili abnormalnim električnim potencijalom nosne sluznice karakterističnim za CF.
TOBI Podhaler inhalation powder, hard capsules consist of a white to almost white powder for inhalation filled into clear colourless hard capsules with “NVR AVCI” imprinted in blue ink on one part of the capsule and the Novartis logo imprinted in blue on the other part of the capsule. 
TOBI Podhaler prašak inhalata, tvrde kapsule sastoji se od bijelog do gotovo bijelog praška za inhalaciju kojim su napunjene prozirne, bezbojne, tvrde kapsule s oznakom „NVR AVCI“ otisnutom plavom bojom na jednom dijelu kapsule i Novartisovim logotipom otisnutim plavom bojom na drugom dijelu kapsule.
A population pharmacokinetic analysis for TOBI Podhaler in cystic fibrosis patients estimated the apparent volume of distribution of tobramycin in the central compartment to be 84.1 litres for a typical CF patient. 
Analiza populacijske farmakokinetike za TOBI Podhaler u bolesnika s cističnom fibrozom procijenila je prividni volumen distribucije tobramicina u središnjem odjeljku na 84,1 litru za tipičnog bolesnika s
TOBI Podhaler is supplied in monthly packs containing 4 weekly cartons and a reserve Podhaler device in its storage case. 
TOBI Podhaler pakiran je u mjesečnim pakiranjima koja sadrže 4 tjedne kutije i rezervni inhalator Podhaler u svom spremniku.
A population pharmacokinetic analysis for TOBI Podhaler in cystic fibrosis patients aged 6 to 66 years estimated the apparent serum clearance of tobramycin to be 14 litres/h. 
Analiza populacijske farmakokinetike za TOBI Podhaler u bolesnika s cističnom fibrozom u dobi od 6 do 66 godina procijenila je prividni klirens tobramicina iz seruma na 14 litara/h.
One capsule contains 28 mg tobramycin. 
Jedna kapsula sadrži 28 mg tobramicina.
• When you start a new weekly pack of capsules, use the new Podhaler device that is supplied in the pack. 
• Kada otvorite novo tjedno pakiranje kapsula, upotrijebite novi uređaj Podhaler koji je priložen u pakiranju.
See also section 4.2 and “Monitoring of serum tobramycin concentrations” below. 
Vidjeti također dio 4.2 i „Praćenje koncentracije tobramicina u serumu“ u nastavku.
What TOBI Podhaler is and what it is used for What you need to know before you take TOBI Podhaler How to take TOBI Podhaler Possible side effects 
Što je TOBI Podhaler i za što se koristi Što morate znati prije nego počnete uzimati TOBI Podhaler Kako uzimati TOBI Podhaler
The use of TOBI Podhaler in patients with clinically significant haemoptysis should be undertaken or continued only if the benefits of treatment are considered to outweigh the risks of inducing further haemorrhage. 
Podhalera u bolesnika s klinički značajnom hemoptizom treba započeti ili nastaviti samo ako se smatra da koristi liječenja premašuju rizike od izazivanja daljnjeg krvarenja.
Strains of Pseudomonas can become resistant to treatment with an antibiotic over time. 
Pseudomonas tijekom vremena mogu postati otporni na liječenje.
Patientreported convenience and overall treatment satisfaction (as collected through a patient-reported outcomes questionnaire) were consistently higher with TOBI Podhaler compared with tobramycin nebuliser solution in each cycle. 
Praktičnost i općenito zadovoljstvo liječenjem prema prijavama bolesnika (prikupljenima kroz upitnike za bolesnike o ishodima) bili su dosljedno viši s TOBI Podhalerom u usporedbi s tobramicin otopinom za nebulizator u svakom ciklusu.
Mylan IRE Healthcare Limited Unit 35/36 Grange Parade, Baldoyle Industrial Estate, Dublin 13 Ireland 
Unit 35/36 Grange Parade, Baldoyle Industrial Estate, Dublin 13
TOBI Podhaler capsules must not be swallowed. 
TOBI Podhaler kapsule se ne smiju gutati.
TOBI Podhaler is indicated for the suppressive therapy of chronic pulmonary infection due to Pseudomonas aeruginosa in adults and children aged 6 years and older with cystic fibrosis. 
TOBI Podhaler je indiciran za supresivno liječenje kronične plućne infekcije uzrokovane bakterijom Pseudomonas aeruginosa u odraslih i djece u dobi od 6 i više godina s cističnom fibrozom.
Adequate data do not exist for the use of TOBI Podhaler in patients after organ transplantation. 
Ne postoje primjereni podaci za primjenu TOBI Podhalera u bolesnika nakon presađivanja organa.
The systemic exposure to tobramycin after inhalation of TOBI Podhaler is expected to be primarily from the inhaled portion of the medicinal product as tobramycin is not absorbed to any appreciable extent when administered via the oral route. 
Očekuje se da će sistemska izloženost tobramicinu nakon inhalacije TOBI Podhalera u prvom redu biti iz inhaliranog dijela lijeka, budući da se tobramicin ne apsorbira u značajnoj mjeri kada se primjenuje peroralnim putem.
Each weekly carton contains 56 x 28 mg capsules (7 blisters with 8 capsules per blister), and a Podhaler device in its storage case. 
Svaka tjedna kutija sadrži 56 x 28 mg kapsula (7 blistera s 8 kapsula po blisteru), i uređaj Podhaler u svom spremniku.
Do not push capsule through foil. 
Ne gurati kapsulu kroz foliju.
MIC increases observed were in large part reversible during offtreatment periods. 
Uočena povišenja MIK-a velikim su dijelom bila reverzibilna tijekom razdoblja neuzimanja terapije.
• Never blow into the mouthpiece of the device. 
• Nikada ne pušite u nastavak za usta na uređaju.
If a patient reports tinnitus or hearing loss during TOBI Podhaler therapy the physician should consider referring them for audiological assessment. 
Ako bolesnik prijavi tinitus ili gubitak sluha tijekom terapije TOBI Podhalerom, liječnik treba razmotriti upućivanje tog bolesnika na audiološku obradu.
If there is evidence of continued therapy-induced cough with TOBI Podhaler, the physician should consider whether an approved tobramycin nebuliser solution should be used as an alternative treatment. 
Ako postoje dokazi o kontinuiranom kašlju izazvanom terapijom TOBI Podhalerom, liječnik treba razmotriti odobrenu tobramicin otopinu za nebulizator kao alternativnu terapiju.
The Podhaler inhalation device and its storage case are made from plastic materials (polypropylene). 
Podhaler inhalator i spremnik za njegovo čuvanje napravljeni su od plastičnih materijala
If you are breast feeding, you should talk to your doctor before taking this medicine. 
Ako dojite, obratite se svom liječniku prije uzimanja ovog lijeka.
Based upon in vitro data and/or clinical trial experience, the organisms associated with pulmonary infections in CF may be expected to respond to TOBI Podhaler therapy as follows: 
Na osnovi in vitro podataka i/ili iskustava iz kliničkih ispitivanja, može se očekivati sljedeća osjetljivost organizama povezanih s plućnim infekcijama kod CF-a na TOBI Podhaler: Osjetljivi
To puncture capsule, hold the inhaler with the mouthpiece down, press the button firmly with your thumb as far as it will go, then release the button. 
Da biste probušili kapsulu, držite inhalator s nastavkom za usta okrenutim prema dolje, čvrsto pritisnite tipku palcem do kraja i zatim otpustite tipku.
• Do not press the piercing button more than once at a time. 
• Ne pritišćite tipku za probijanje kapsule više od jedanput.
• Put the capsule back into the inhaler chamber (step 6) 
• Vratite kapsulu u komoru inhalatora (korak 6)
Inhalation powder, hard capsules 56 capsules + 1 inhaler 
Prašak inhalata, tvrde kapsule 56 kapsula + 1 inhalator
If the capsule appears to be unpunctured, place it back into the inhaler, press the button firmly as far as it goes and take another two inhalations from the capsule. 
Ako izgleda da kapsula nije probušena, vratite je u inhalator, čvrsto pritisnite tipku do kraja i napravite još dvije inhalacije iz kapsule.
Inhaling medicines can cause chest tightness and wheezing and this can happen immediately after inhalation of TOBI Podhaler. 
Inhalacija lijekova može uzrokovati stezanje u prsnom košu i piskanje, a to se može dogoditi odmah nakon inhalacije TOBI Podhalera.
• When you start a new weekly pack of capsules, use the new inhaler that is supplied in the pack. 
• Kada otvorite novo tjedno pakiranje kapsula, upotrijebite novi inhalator koji je priložen u pakiranju.
Furthermore, an improvement of 6% in percent predicted FEV1 was obtained in about 30% versus 36% of the adult patients in the TOBI Podhaler and TOBI nebuliser solution group respectively. 
Nadalje, postignuto je poboljšanje od 6% u postotku predviđenog FEV1 u oko 30% odraslih bolesnika u skupini koja je primala TOBI Podhaler u odnosu na 36% onih koji su primali TOBI otopinu za nebulizator.
At the end of a 4-week dosing cycle of TOBI Podhaler (112 mg twice daily), maximum serum concentration of tobramycin 1 hour after dosing was 1.99 ± 0.59 µg/ml. 
Na kraju 4-tjednog ciklusa doziranja TOBI Podhalera (112 mg dvaput na dan), maksimalna koncentracija tobramicina u serumu 1 sat nakon doze bila je 1,99 ± 0,59 µg/ml.
Before putting the mouthpiece in your mouth, breathe out fully, away from the inhaler. 
Prije nego što u usta stavite nastavak za usta, izdahnite do kraja i to dalje od inhalatora.
• 4 capsules in the morning to be inhaled using the Podhaler device. 
• 4 kapsule ujutro koje se inhaliraju uz korištenje Podhaler uređaja.
Always store inhaler in its case. 
Inhalator uvijek čuvati u njegovom spremniku.
• 4 capsules in the evening to be inhaled using the Podhaler device. 
• 4 kapsule uvečer koje se inhaliraju uz korištenje Podhaler uređaja.
In the active-controlled study, administration of a TOBI Podhaler dose was faster with a mean difference of approximately 14 minutes (6 minutes vs. 20 minutes with the nebuliser solution). 
Podhalera bila je brža uz srednju vrijednost razlike od otprilike 14 minuta (6 minuta u odnosu na 20 minuta s otopinom za nebulizator).
• Discard all the empty capsules. 
• Uklonite sve prazne kapsule.
If TOBI Podhaler is swallowed, don't worry but tell your doctor as soon as possible. 
Ako progutate TOBI Podhaler, ne brinite ali što prije to recite svom liječniku.
• Do not swallow TOBI Podhaler capsules. 
• Ne gutajte kapsule TOBI Podhaler.
In patients with a predisposing risk due to previous prolonged, systemic aminoglycoside therapy it may be necessary to consider renal and audiological assessment before initiating TOBI Podhaler therapy. 
bolesnika s predisponirajućim rizikom uzrokovanim prethodnom produljenom sistemskom terapijom aminoglikozidima moglo bi biti potrebno razmotriti bubrežne i audiološke pretrage prije početka terapije TOBI Podhalerom.
Adult patients tended to discontinue more frequently for tolerability reasons with TOBI Podhaler than with the nebuliser solution. 
Odrasli bolesnici bili su skloniji učestalijim prekidima liječenja zbog manje podnošljivosti s TOBI Podhalerom nego s otopinom za nebulizator.
While the volume was shown to vary with body mass index (BMI) and lung function (as FEV1% predicted), model-based simulations showed that peak (Cmax) and trough (Ctrough) concentrations were not impacted markedly with changes in BMI or lung function. 
(kao FEV1% predviđenog), simulacije temeljene na modelu pokazale su da na vršne (Cmax) i najniže (Ctrough) koncentracije nisu znatno utjecale promjene BMI-ja ili plućne funkcije.
Productive cough 
Produktivan kašalj
Each hard capsule contains 28 mg tobramycin. 
Svaka tvrda kapsula sadrži 28 mg tobramicina.
• Never place a TOBI Podhaler capsule directly into the mouthpiece of the device. 
• Nikad ne stavljajte TOBI Podhaler kapsulu izravno u nastavak za usta na uređaju.
It is bactericidal at concentrations equal to or slightly greater than inhibitory concentrations. 
U koncentracijama koje su jednake ili malo veće od inhibitornih koncentracija djeluje baktericidno.
Caution should be exercised when prescribing TOBI Podhaler to patients with known or suspected auditory or vestibular dysfunction. 
Potreban je oprez kod propisivanja TOBI Podhalera bolesnicima s potvrđenom ili suspektnom auditivnom ili vestibularnom disfunkcijom.
Set the mouthpiece aside on a clean, dry surface. 
Odložite nastavak za usta sa strane na čistu, suhu površinu.
The powder in the capsules is for you to inhale. 
Prašak u kapsulama namijenjen je za udisanje.
Tobramycin is primarily excreted unchanged in the urine and renal function is expected to affect the exposure to tobramycin. 
Tobramcin se prvenstveno izlučuje nepromijenjen u mokraći pa se očekuje da će bubrežna funkcija utjecati na izloženost tobramicinu.
4.4 Special warnings and precautions for use 
4.4 Posebna upozorenja i mjere opreza pri uporabi Ototoksičnost
• Do not wash the inhaler with water. 
• Ne perite inhalator vodom.
How much TOBI Podhaler to take 
Koliko TOBI Podhalera uzeti
• Set the mouthpiece aside on a clean, dry surface. 
• Odložite nastavak za usta na čistu, suhu površinu.
Reinspect capsule. 
Ponovno provjerite kapsulu.
Inhale the capsule - 2nd breath: 
Inhalirajte kapsulu - drugi udisaj:
• Put the capsule back into the inhaler chamber (step 6). 
• Vratite kapsulu u komoru inhalatora (korak 6).
A majority of the patients were tobramycin-experienced adults with chronic pulmonary P. aeruginosa infection. 
Većina bolesnika bili su odrasle osobe s kroničnom plućnom infekcijom P. aeruginosa koji su već imali iskustva s tobramicinom.
What TOBI Podhaler is and what it is used for What TOBI Podhaler is 
Što je TOBI Podhaler i za što se koristi Što je TOBI